Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thyrotropin alfa + iodine-131
- Development stage
- Phase 4
- Lead developer
- Sanofi
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Oral
01
Overview
Thyrotropin alfa + iodine-131 is a combination therapy used primarily in the management of well-differentiated thyroid cancer, especially after thyroidectomy. Thyrotropin alfa is a recombinant form of human thyroid stimulating hormone (TSH) that binds to TSH receptor on residual thyroid cells or tissues, stimulating uptake of radioactive iodine. This enhances the effectiveness of radioiodine imaging and ablation by increasing iodine uptake in any remaining thyroid tissue or cancer cells[1][5][6]. Iodine-131 is a radioisotopic agent that emits beta and gamma radiation; it selectively accumulates in thyroid tissue due to natural iodine uptake mechanisms, leading to targeted destruction of remnant or malignant cells[8]. The combination allows for effective diagnostic evaluation (via stimulated thyroglobulin testing and imaging) as well as therapeutic ablation without requiring patients to undergo prolonged hypothyroidism from withdrawal of endogenous TSH stimulation[1][5][6][8].
- Other names
- thyroid stimulating hormone recombinant + sodium iodide I-131rhTSH + I-131
02
Targets
NIS (Human sodium iodide symporter)TSHR (Thyroid-stimulating hormone receptor)
Beyond the preview
Go deeper on thyrotropin alfa + iodine-131.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thyrotropin alfa + iodine-131.